Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized in ICU~* Receiving Continuous hemodialysis~* Prescribed ertapenem~* Informed consent granted~Exclusion Criteria:~* \< 18 years of age~* Allergy to ertapenem or other carbapenem antibiotic~* Severe, life-threatening reaction to penicillin or cephalosporins~* Patients experiencing or with history of CNS disorders (eg: seizure, stroke)~* Patients experiencing CNS infection~* Inability to complete 24 hours of CVVHD~* Concurrent use of other extracorporeal therapies such as extracorporeal membrane oxygenation, plasmapheresis or intermittent hemodialysis~* Inability to obtain informed consent~* Pregnant and/or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ertapenem (Type: EXPERIMENTAL): subjects will receive ertapenem while receiving CVVHD

Based on this trial design, predict the completion outcome and termination type (if applicable).